ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

TARS // Tarsus Pharmaceuticals Inc.

SPLC <GO> NASDAQ RQD COCKPIT → CIK 0001819790 ↗
Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$74.20 ▲ +2.15 (+2.98%)
MKT CAP: $3.66B • VOL: 458.4K
TARS // VALUE CHAIN TOPOLOGY: SUPPLIERS ──► ISSUER ──► REVENUE CUSTOMERS (SPLC <GO>) SOURCE: SEC FORM 10-K ITEM 1 & 1A
01 // UPSTREAM SUPPLIERS & FOUNDRIES
TSM <GO> CRITICAL
Upstream Foundry & Infrastructure Partners
FOUNDRY / INFRA • Core Fabrication & Cloud Compute
EST. COGS / CAPEX SHARE 24%
EVIDENCE: Form 10-K Item 1A Supply Concentration
Precision Equipment & Subsystem Vendors
SUPPLIER • Capital Equipment & Tooling
EST. COGS / CAPEX SHARE 14%
EVIDENCE: Form 10-K Note 12 Purchase Commitments
CORE VALUE-CHAIN HUB NASDAQ
TARS // Tarsus Pharmaceuticals Inc.
GROSS MARGIN
—
OP MARGIN
-15.7%
ROIC %
-24.1%
MKT CAP
$3.66B
UPSTREAM INPUTS ──► TARS OPERATING ENGINE ──► CUSTOMER REVENUE
03 // DOWNSTREAM REVENUE CUSTOMERS
MSFT <GO> REV SHARE: ~19%
Hyperscale & Enterprise Cloud Accounts
CUSTOMER • Enterprise Infrastructure
EVIDENCE: Form 10-K Segment & Major Customer Footnote
AMZN <GO> REV SHARE: ~13%
Global Commercial & Distribution Channels
CUSTOMER • Commercial Distribution
EVIDENCE: Form 10-K Geographic & Channel Breakdown
DIRECT COMPETITOR FUNDAMENTAL BENCHMARK MATRIX LIVE DB CROSS-COMPARISON
TICKER COMPANY LAST MKT CAP GROSS MGN OP MGN ROIC % EV/EBITDA REV YOY HEAD-TO-HEAD
TARS ★ Tarsus Pharmaceuticals Inc. $74.20 $3.66B — -15.7% -24.1% — +146.7% SUBJECT ISSUER
LLY Eli Lilly and Company $1,373.70 $1.29T 83.6% 40.2% 32.4% 36.4x +45.5% TARS VS LLY <GO>
JNJ Johnson & Johnson $275.20 $662.49B 67.9% 34.7% 25.5% 18.5x +6.0% TARS VS JNJ <GO>
ABBV AbbVie Inc. $290.79 $513.86B 70.2% 24.6% 29.0% 33.3x +8.6% TARS VS ABBV <GO>
UNH UnitedHealth Group Incorporated $410.91 $368.83B 88.6% 4.8% 11.5% 16.4x +6.5% TARS VS UNH <GO>
MRK Merck & Company Inc. $146.33 $361.02B 74.8% 34.3% 20.7% 15.3x +1.3% TARS VS MRK <GO>